# A Study of LY2484595 in Japanese Subjects

Study · id `cardio:ct-nct01375075` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01375075](<https://clinicaltrials.gov/study/NCT01375075>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01375075

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 165 participants.

## Technical summary

Registry record NCT01375075. Randomized; quadruple masking; primary purpose treatment. Start 2011-06 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2018-10-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 165 participants (enrolled count; ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Start date: 2011-06 (registry gives no type) (ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Results first posted: 2018-10-25 (ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT01375075, source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01375075-2018-10-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of LY2484595 in Japanese Subjects
- Condition: Dyslipidemias
- Intervention (Drug): LY2484595
- Intervention (Drug): Placebo
- Intervention (Drug): Atorvastatin
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: ee86856810f822f1e94883dc6b5e7bcc32a1e39bc76aba26ab9d9d3440b7d29d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
